April 22nd 2024
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Dr. Perl on Survival Improvement With Gilteritinib in FLT3+ AML
April 12th 2019Alexander E. Perl, MD, discusses results from the phase III ADMIRAL trial, which demonstrated a significant improvement in overall survival in patients with <em>FLT3</em>-mutated acute myeloid leukemia treated with the FLT3 inhibitor gilteritinib.
Watch
Daver Explains Treatment Considerations in Case Study of a Patient With FLT3-ITD+ AML
April 10th 2019Naval G. Daver, MD, discusses treatment options and the data these options are based off of for the management of acute myeloid leukemia, based on a case scenario of a patient with <em>FLT3 </em>internal tandem duplication –positive acute myeloid leukemia.
Read More
NDA Review Period Extended by FDA for Quizartinib in FLT3-ITD+ AML
April 5th 2019The review period on the new drug application for quizartinib as a treatment for adult patients with relapsed/refractory <em>FLT3</em>-ITD–positive acute myeloid leukemia has been extended by the FDA by 3 months. This provides the FDA with additional time to review more data supplied by Daiichi Sankyo, the manufacturer of the FLT3 inhibitor.
Read More
Gilteritinib Improves Survival in Patients With Relapsed/Refractory FLT3+ AML
April 2nd 2019Overall survival was significantly improved in patients with relapsed/refractory <em>FLT3</em> mutation–positive acute myeloid leukemia who were treated with the FLT3 inhibitor gilteritinib, according to updated findings presented during the 2019 AACR Annual Meeting.
Read More
Mutational Testing an Important Factor in AML Treatment Paradigm, Smith Explains
March 27th 2019During a <em>Targeted Oncology</em> live case-based peer perspectives program, B. Douglas Smith, MD, discussed his clinical consideration for the management of acute myeloid leukemia. Smith explained his treatment decisions during the dinner event in 2 case scenarios of patients with AML.
Read More
Jabbour Reviews TKI Options in Case Study of Chronic Phase CML
March 21st 2019During a <em>Targeted Oncology </em>case-based peer perspectives program, Elias Jabbour, MD, discussed his clinical considerations for the management of chronic myeloid leukemia in chronic phase. Jabbour explained his treatment decisions during the live event based on a case scenario of a patient with CML-CP.
Read More
VA Broadens Comprehensive Care by Providing Genomic Testing in Advanced Cancer
March 8th 2019Genomic testing could increasingly be utilized to guide treatment decisions for Veteran patients with cancer. Two recent announcements confirm an emerging focus from Veterans Affairs on genetic testing that provides more informed and tailored cancer care for US Veterans.
Read More
sNDA Submitted to FDA for Approval of Venetoclax/Obinutuzumab in Treatment Naive CLL
March 8th 2019The combination regimen of venetoclax and obinutuzumab is seeking FDA approval; a supplemental new drug application has been submitted to the FDA for the combination as a treatment for patients with previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions, according to an announcement from Genentech (Roche).
Read More
Encouraging Findings Seen With Iomab-B as Novel Conditioning for HSCT in AML
February 26th 2019All but 1 of the first 19 patients with relapsed/refractory AML randomized to receive iodine-131 apamistamab had a complete response and went on to have successful engraftment of allogeneic hematopoietic stem cell transplant, according to preliminary results from the ongoing, randomized, phase III SIERRA trial that were presented at the 2019 Transplantation and Cellular Therapy Meetings.
Read More
Adding Ibrutinib to CAR T-Cell Therapy Increases Response Rates in CLL
February 22nd 2019Adding ibrutinib to CAR T-cell therapy led to improved responses in patients with relapsed/refractory chronic lymphocytic leukemia, according to preliminary findings presented at the 2019 Transplantation and Cellular Therapy Meetings.
Read More
Ivosidenib Receives Priority Review From FDA for Frontline IDH1+ AML
February 21st 2019A supplemental new drug application for ivosidenib has been granted a priority review designation by the FDA for the frontline treatment of patients <em>IDH1</em>-mutant acute myeloid leukemia who are ineligible for standard chemotherapy, according to Agios, the manufacturer of ivosidenib.
Read More
MDS, AML Risks Rise Significantly Following Chemotherapy in Most Solid Cancers
February 15th 2019The first attempt to quantify therapy-related myelodysplastic syndrome or acute myeloid leukemia in the era of widespread platinum-based chemotherapy has found that tMDS/AML risks were statistically significantly elevated after chemotherapy for 22 of 23 solid cancers, according to a new study in <em>JAMA Oncology.</em>
Read More
Novel Analog Demonstrates Efficacy in Early Recurrent/Refractory AML
February 13th 2019A novel agent demonstrated efficacy in treating patients with early recurrent or refractory acute myeloid leukemia when administered via continuous intravenous infusion, according to results from a phase I/II trial recently published in <em>Cancer. </em>The agent was also well tolerated among patients.
Read More
Targeted Therapy Pioneers Slamon and Druker Awarded Sjoberg Prize
February 8th 2019Clinical researchers Dennis Slamon, MD, PhD, and Brian Druker, MD, were recently honored with the 2019 Sjöberg Prize for their ground-breaking contributions toward targeted therapy for patients with breast cancer and chronic myeloid leukemia, respectively.
Read More
Expert Highlights Duvelisib Benefit for Patients With CLL
February 1st 2019In an interview with <em>Targeted Oncology</em>, Ian W. Flinn, MD, PhD, discussed the potential impact of duvelisib on patients with CLL. Flinn serves as the lead investigator of the DYNAMO and DUO studies in duvelisib.
Read More
Ibrutinib Plus Obinutuzumab Approved by FDA as Frontline CLL/SLL Treatment
January 28th 2019The combination of ibrutinib and obinutuzumab has gained FDA approval for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on data from the phase III iLLUMINATE trial.
Read More